Barrett & Company Inc. Acquires 50,741 Shares of Johnson & Johnson $JNJ

Key Points

• Barrett & Company increased its Johnson & Johnson stake by 531.5% in the third quarter, purchasing 50,741 additional shares and bringing its holdings to 60,288 shares valued at approximately $15.96 million.
• Johnson & Johnson reported quarterly earnings and revenue slightly above analyst expectations, with revenue up 5.9% year over year, and declared a quarterly dividend of $1.34 per share, yielding about 2.0% annually.
• Oncology developments were positive: JNJ-6143 and RYBREVANT FASPRO showed encouraging early clinical results, while ERLEADA reduced recurrence or death risk by 62% in a high-risk prostate-cancer study. Analysts maintain a “Moderate Buy” consensus, though clinical risks and recent insider selling remain considerations.

Barrett & Company Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 531.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,288 shares of the company's stock after buying an additional 50,741 shares during the period. Johnson & Johnson accounts for approximately 4.3% of Barrett & Company Inc.'s portfolio, making the stock its 5th largest position. Barrett & Company Inc.'s holdings in Johnson & Johnson were worth $15,961,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Outlook Capital Management LLC purchased a new position in shares of Johnson & Johnson in the second quarter worth $28,000. Matrix Trust Co increased its holdings in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Montgomery Financial Services LLC purchased a new position in shares of Johnson & Johnson during the 2nd quarter valued at $43,000. Polaris Financial Partners purchased a new position in shares of Johnson & Johnson in the third quarter valued at about $56,000. Finally, Bullseye Investment Management LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $63,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Promising prostate-cancer data: Experimental drug JNJ-6143 produced tumor-response rates of roughly 69% to 75% in heavily pretreated patients with advanced prostate cancer. The results support further development of the first-in-class RIPTAC drug, although the evidence remains early-stage. What Do Johnson & Johnson Cancer Trial Wins Mean For Its Stock?
• Positive Sentiment: RYBREVANT expansion potential: A subcutaneous RYBREVANT FASPRO combination generated a 77% overall response rate in first-line treatment of advanced head and neck cancer. The findings support the ongoing Phase 3 OrigAMI-5 trial and could broaden the commercial opportunity for a key oncology franchise. RYBREVANT FASPRO Head and Neck Cancer Results
• Positive Sentiment: ERLEADA showed a meaningful benefit: Johnson & Johnson said using ERLEADA before and after surgery reduced the risk of recurrence or death by 62% versus surgery alone in high-risk localized or locally advanced prostate cancer, potentially supporting broader adoption. ERLEADA Surgical Study Results
• Neutral Sentiment: ETF activity showed net selling of JNJ, but this is generally a short-term trading signal rather than a change in the company’s fundamentals.
• Negative Sentiment: An expected orthopedics merger with Smith & Nephew collapsed over leadership disagreements, removing a potential strategic opportunity. The strong cancer data also comes with clinical and regulatory risks because several programs remain in relatively early development.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $266.38 on Tuesday. The firm has a market cap of $641.25 billion, a price-to-earnings ratio of 40.36, a PEG ratio of 2.61 and a beta of 0.21. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company's 50 day moving average is $265.35 and its 200 day moving average is $245.32.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. Johnson & Johnson's revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is presently 81.21%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president owned 16,994 shares of the company's stock, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 64,515 shares of company stock valued at $17,271,766. Corporate insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JNJ. HSBC upped their target price on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 14th. Leerink Partners decreased their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. Scotiabank restated an "outperform" rating and issued a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Citigroup boosted their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.